Ventyx Biosciences, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
An insider group, including Somasundaram Subramaniam, has ceased beneficial ownership of Ventyx Biosciences, Inc. following its acquisition by Eli Lilly and Company for $14.00 per share in cash.
Ventyx Biosciences, Inc. has entered into a definitive merger agreement to be acquired by Eli Lilly and Company for $14.00 per common share in cash.
Ventyx Biosciences, Inc. has entered into a definitive merger agreement to be acquired by Eli Lilly and Company for $14.00 per common share in cash.
Ventyx Biosciences CEO Raju Mohan has increased his beneficial ownership in the company to 6.0% through a combination of direct purchases, option exercises, and RSU vesting.
SCHEDULE 13D/A: NSV Entities Amend Ventyx Biosciences Ownership, Disclosing Share Distribution and Reduced Stakes
NSV Partners III, L.P., NSV Partners III GP, LLC, and Somasundaram Subramaniam have filed an Amendment No. 13 to their Schedule 13D, detailing a distribution of 1,335,450 Ventyx Biosciences common shares by NSV Investments I, L.P. and the subsequent reduction in their beneficial ownership percentages.
SCHEDULE 13D/A: Major Shareholder Amends Ventyx Biosciences Stake Following Internal Share Distribution
NSV Investments I, L.P. and affiliated entities have updated their beneficial ownership in Ventyx Biosciences, Inc. through an Amendment No. 12 to Schedule 13D, reflecting a distribution of 1.73 million shares to limited partners.